Macrophage migration inhibitory factor contributes to immunopathogenesis during Plasmodium yoelii 17XL infection

Salazar-Castañón, Víctor H.; Juárez-Avelar, Imelda; Legorreta-Herrera, Martha; Rodrı́guez-Sosa, Miriam

doi:10.3389/fcimb.2022.968422

Cited by 3 publications

(1 citation statement)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An opposite trend was observed in a study on Plasmodium yoelii infections [90]. In this research, MIF-deficient mice showed lower parasitemia and delayed host mortality.…”

Section: Parasitic Infectionscontrasting

confidence: 70%

The Role of Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (D-DT/MIF-2) in Infections: A Clinical Perspective

Breidung,

Megas,

Freytag

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Macrophage migration inhibitory factor (MIF) and its homolog, D-dopachrome tautomerase (D-DT), are cytokines that play critical roles in the immune response to various infectious diseases. This review provides an overview of the complex involvement of MIF and D-DT in bacterial, viral, fungal, and parasitic infections. The role of MIF in different types of infections is controversial, as it has either a protective function or a host damage-enhancing function depending on the pathogen. Depending on the specific role of MIF, different therapeutic options for MIF-targeting drugs arise. Human MIF-neutralizing antibodies, anti-parasite MIF antibodies, small molecule MIF inhibitors or MIF-blocking peptides, as well as the administration of exogenous MIF or MIF activity-augmenting small molecules have potential therapeutic applications and need to be further explored in the future. In addition, MIF has been shown to be a potential biomarker and therapeutic target in sepsis. Further research is needed to unravel the complexity of MIF and D-DT in infectious diseases and to develop personalized therapeutic approaches targeting these cytokines. Overall, a comprehensive understanding of the role of MIF and D-DT in infections could lead to new strategies for the diagnosis, treatment, and management of infectious diseases.

show abstract

“…An opposite trend was observed in a study on Plasmodium yoelii infections [90]. In this research, MIF-deficient mice showed lower parasitemia and delayed host mortality.…”

Section: Parasitic Infectionscontrasting

confidence: 70%

The Role of Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (D-DT/MIF-2) in Infections: A Clinical Perspective

Breidung,

Megas,

Freytag

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

Thymic atrophy induced by Plasmodium berghei ANKA and Plasmodium yoelii 17XL infection

Corral-Ruiz,

Pérez-Vega,

Galán-Salinas

et al. 2023

Immunology Letters

View full text Add to dashboard Cite

Taurine potentiates artemisinin efficacy against malaria by modulating the immune response in Plasmodium berghei-infected mice

Li,

Jiang,

et al. 2024

Parasites Vectors

View full text Add to dashboard Cite

Background Artemisinin (ART) is a frontline drug for the treatment of malaria; however, the emergence of ART-resistant Plasmodium strains necessitates increasing ART sensitivity. Given that taurine (TAU) has been shown to have immunomodulatory activity, we investigated the effects of TAU as an adjunct therapy to ART in mice infected with Plasmodium berghei. Methods Mice infected with P. berghei ANKA strain (P. berghei ANKA) were treated with TAU alone, ART alone or a combination of TAU and ART (TAU + ART), and their survival time and parasitaemia were recorded. The cytotoxic effects of TAU and ART were subsequently assessed. The expression levels of inflammasome-related genes and inflammatory factors in mice infected with P. berghei ANKA were analysed in relation to those in mice treated with TAU alone, ART alone or the TAU + ART combination. The therapeutic effects were further evaluated by histological analysis and measurement of the spleen index. Results Compared with the control mice, P. berghei ANKA-infected mice treated with ART in combination with TAU presented significantly lower parasitaemia and prolonged survival. The combined treatment resulted in significant reductions in the expression levels of inflammasome-related genes in the spleen, including absent in melanoma 2 (AIM2), caspase-1, NOD-, LRR- and pyrin domain-containing protein 3 (Nlrp3), Nlrp1b, Nlrp1b, NLR family CARD domain containing 4 (Nlrc4), Nlrp6, nucleotide binding oligomerization domain containing 1 (NOD1) and NOD2, and decreases in the levels of inflammatory cytokines in the serum, including interleukin (IL)-12p70, tumour necrosis factor-alpha, monocyte chemoattractant protein-1, IL-10 and IL-6. Histopathological analysis confirmed that TAU + ART combination treatment reduced spleen pathology caused by P. berghei ANKA infection. Conclusions The findings indicate that TAU potentiates ART efficacy by modulating the immune response in P. berghei-infected mice. Graphical Abstract

show abstract

Macrophage migration inhibitory factor contributes to immunopathogenesis during Plasmodium yoelii 17XL infection

Cited by 3 publications

References 86 publications

The Role of Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (D-DT/MIF-2) in Infections: A Clinical Perspective

The Role of Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (D-DT/MIF-2) in Infections: A Clinical Perspective

Thymic atrophy induced by Plasmodium berghei ANKA and Plasmodium yoelii 17XL infection

Taurine potentiates artemisinin efficacy against malaria by modulating the immune response in Plasmodium berghei-infected mice

Contact Info

Product

Resources

About